SAN DIEGO–(BUSINESS WIRE)–Dexcom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, commends the expansion of CGM Medicare coverage to include people with diabetes using all types of insulin, as well as certain non-insulin-using individuals who have a history of problematic hypoglycemic events.* The updated Medicare policy is the biggest single expansion of CGM coverage in the U.S. to date. Read more >
- The BUZZ / News
- Publications
- MarketplaceAutomationCompoundingContamination ControlDelivery & ShippingDistributionFacilitiesFinanceManufacturingMerchandisingPatient CareHighlighted Practice SettingsProfessional DevelopmentProfessional ServicesSoftware
- Business Management, Operations, ERP
- Clinical Monitoring, Surveillance, Insights
- Controlled Substance Reporting
- Clinical Decision Support, Point of Care Reference, Dosing, DUR
- Drug Diversion Monitoring, Diversion Prevention
- Error Prevention, Drug Validation
- eMAR, EMR, EHR, Bedside Verification
- Formulary Management
- IV Workflow Management
- Long-Term Care Operation Management
- Medication Inventory Management & Procurement
- Pharmacy Management Systems, Workflow
- Stewardship Resources (Antibiotic, Opioid, etc)
Unit DoseWorkflow - Multimedia Content
- Career Center
- Market Intelligence
- Company
